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Frequency of pathogenic germline variants
in BRCA1, BRCA2, PALB2, CHEK2 and TP53
in ductal carcinoma in situ diagnosed in
women under the age of 50 years
Christos Petridis1,2, Iteeka Arora1, Vandna Shah1, Anargyros Megalios1, Charlotte Moss1, Anca Mera1,
Angela Clifford1, Cheryl Gillett1, Sarah E. Pinder1, Ian Tomlinson3, Rebecca Roylance4, Michael A. Simpson2 and
Elinor J. Sawyer1,5*
Abstract
Introduction: Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive ductal breast cancer, and
approximately 20% of screen-detected tumours are pure DCIS. Most risk factors for breast cancer have similar
associations with DCIS and IDC; however, there is limited data on the prevalence of the known high and moderate
penetrance breast cancer predisposition genes in DCIS and which women with DCIS should be referred for genetic
screening.
The aim of this study was to assess the frequency of germline variants in BRCA2, BRCA1, CHEK2, PALB2 and TP53 in
DCIS in women aged less than 50 years of age.
Methods: After DNA extraction from the peripheral blood, Access Array technology (Fluidigm) was used to amplify
all exons of these five known breast cancer predisposition genes using a custom made targeted sequencing panel
in 655 cases of pure DCIS presenting in women under the age of 50 years together with 1611 controls.
Results: Case-control analysis revealed an excess of pathogenic variants in BRCA2 (OR = 27.96, 95%CI 6.56–119.26,
P = 2.0 × 10−10) and CHEK2 (OR = 8.04, 95%CI 2.93–22.05, P = 9.0 × 10−6), with weaker associations with PALB2 (P = 0.
003), BRCA1 (P = 0.007) and TP53 (P = 0.02). For oestrogen receptor (ER)-positive DCIS the frequency of pathogenic
variants was 9% under the age of 50 (14% with a family history of breast cancer) and 29% under the age of 40
(42% with a family history of breast cancer). For ER-negative DCIS, the frequency was 9% (16% with a family history
of breast cancer) and 8% (11% with a family history of breast cancer) under the ages of 50 and 40, respectively.
Conclusions: This study has shown that breast tumourigenesis in women with pathogenic variants in BRCA2, CHEK2,
PALB2, BRCA1 and TP53 can involve a DCIS precursor stage and that the focus of genetic testing in DCIS should be on
women under the age of 40 with ER-positive DCIS.
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Introduction
Ductal carcinoma in situ (DCIS) is considered a non-obligate
precursor of invasive breast cancer of ductal/no special type
(IDC) as many IDCs have evidence of associated DCIS at
presentation [1, 2] and the two components have similar gen-
etic changes, suggesting that in the majority of cases the inva-
sive component has arisen from the DCIS [3]. Synchronous
DCIS is more frequent in luminal and HER2-positive IDC
(53% and 63%, respectively) than invasive basal breast cancer
(33%) [4]. Since the introduction of screening mammography,
there has been an increase in the reported incidence of pure
DCIS with no invasive component [5], with about 20% of
screen-detected tumours being pure DCIS [6].
Most non-genetic risk factors for breast cancer have simi-
lar associations with DCIS and IDC, again supporting the
notion that DCIS is a precursor of invasive cancer [7, 8].
Epidemiological studies have shown there is an inherited
predisposition to DCIS, with women with DCIS being 2.4
times more likely to have an affected mother and sister with
breast cancer than controls [9]. One study of almost 40,000
women suggested that the familial relative risk of DCIS may
be greater than that of invasive breast cancer [10], but this
was not confirmed in the Million Women Study, which
showed a similar association with family history for DCIS
and IDC [8].
The familial risk associated with invasive breast cancer is
in part explained by both high-risk rare variants and
low-risk susceptibility loci. We have shown that the majority
of low-risk invasive breast cancer predisposition loci also
predispose to DCIS and, as for invasive disease, different loci
predispose to ER-positive and ER-negative DCIS and high
and low grade DCIS [11]. However, the frequency of patho-
genic high- and moderate-risk variants in DCIS is not clear.
Claus et al. studied 369 women (mean age 53.8 years) with
pure DCIS selected from a case-control study of carcinoma
in situ and found that 2.4% had pathogenic variants in
BRCA2 and 0.8% in BRCA1 [12]. Hall et al. analysed a
highly selected cohort of women with carcinoma in situ
(LCIS and DCIS) that were referred to Myriad for genetic
testing. They found that 5.2% of women with pure carcin-
oma in situ (CIS) had BRCA1/2 mutations (2.3% if women
with a family history of breast cancer were excluded) and
like Claus et al. that BRCA2 mutations were more common
than BRCA1 [13]. Both these studies were performed before
gene panel genetic testing was available, and therefore, other
breast cancer predisposition genes such as PALB2, CHEK2
and TP53 were not assessed.
In this study, we report the frequency of rare variants
in five known breast cancer predisposition genes
(BRCA2, BRCA1, TP53, CHEK2 and PALB2) in 655 cases
of pure DCIS with no invasive disease in women
diagnosed before the age of 50. These cases were in-
cluded in our previous study of low-risk susceptibility
loci in DCIS [11].
Methods
Samples
Six hundred fifty-five cases of pure DCIS with no inva-
sive disease diagnosed in women aged under 50 were in-
cluded in this study, Table 1. The majority of cases (633)
were recruited through the ICICLE study (MREC 08/
H0502/4) from 95 hospitals throughout the UK. This
study was set up with the specific aim of investigating
genetic predisposition to DCIS in the UK. A further 22
cases were recruited through the King’s Health Partners
(KHP) Cancer Biobank (NHS REC ref. 12-EE-0493).
Samples from patients under the age of 50 were selected
for this analysis in order to enrich for cases likely to have
a genetic component to their disease.
All controls were collected through the ICICLE and
GLACIER studies (a similar study of lobular breast can-
cer, MREC 06/Q1702/64) and were identified by asking
patients (cases) from both studies at the time of recruit-
ment to identify female non-blood relatives or friends
who were willing to donate a blood sample. These
healthy volunteers were only eligible if they had no per-
sonal or family (up to second degree) history of invasive
breast cancer, lobular carcinoma in situ (LCIS), DCIS or
benign breast disease. Controls were not age matched
and could be of any age, although older individuals were
preferred (super-controls), as they had lived through
many of their at-risk years.
All participants (cases and controls) donated a blood
sample and were asked to complete a self-administered
paper-based questionnaire on their family history.
Data on grade and oestrogen receptor (ER) status was
ascertained mostly from the hospital pathology reports.
In 200 cases where the grade data was missing from the
report but a tumour block was available, a H&E section
was cut and the DCIS was graded by the study histo-
pathologist (SEP) according to UK and CAP guidelines
[14]. A subset of 81 cases, graded in the pathology re-
port and with a tumour block available, was examined to
assess the reliability of the cytonuclear grade provided
Table 1 ER status and cytonuclear grade of DCIS by age
Age Total ER+ ER− ER unknown High grade Int grade Low grade Grade unknown
40–49 555 345 (62%) 62 (11%) 148 (27%) 345 (62%) 148 (27%) 47 (8%) 15 (3%)
< 40 100 45 (45%) 26 (26%) 29 (29%) 72 (72%) 20 (20%) 7 (7%) 1 (1%)
All 655 390 88 177 417 168 54 16
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by the pathology reports. In the majority of cases
(86.5%), grade was concordant with the pathology re-
port. Nine cases were re-graded as low/intermediate
grade and two cases as high grade. As the study patholo-
gist re-graded the samples on a single H&E section,
rather than all the blocks from an individual case, and in
some cases on re-excision specimens with residual dis-
ease rather than the original excision specimen, the
grade reported in the pathology report, if available, was
used for the purposes of this study.
If ER status was not available from the local histopath-
ology report and the tumour block was available, immu-
nohistochemistry was performed and scored using the
Allred method as previously described [11]. An Allred
score of 3 or more was considered ER+ and that with
scores of 0–2 (approximately equivalent to less than 1%
of nuclei) were regarded as ER−.
Next-generation sequencing
After DNA extraction from the peripheral blood, Access
Array technology (Fluidigm) was used to amplify all
exons of BRCA2, BRCA1, TP53, CHEK2 and PALB2
using a custom made targeted sequencing panel consist-
ing of 321 amplicons (Additional file 1). The Fluidigm
designed primers were supplied in single-plex with for-
ward and reverse primers combined; these were multi-
plexed according to supplier’s instruction to achieve
optimal efficiency. Purified libraries were quantified
using Qubit High Sensitivity Assay Kit, and their average
length size was measured in Tapestation using the
D1000 screentape. The quantity and length size values
obtained from the readings were used to calculate the
final Molar concentration in order to prepare each se-
quencing library at 4 nM containing 960 samples, based
on the following formula:
Molar Concentration in nMð Þ
¼ Concentration in ngð Þ  106  1
649
 
 1
average size in bpð Þ
 
All quantified libraries were subsequently sequenced
on a HiSeq2500 (Illumina).
Bioinformatics analysis
Primer sites from the amplicons were trimmed using
Btrim, and then, sequences were aligned to the reference
genome (http://www.novocraft.com, GRCh37 version)
using Novoalign (Gap opening penalty = 65 and gap ex-
tension penalty = 7 thresholds were applied). Picard
tools (v1.74 https://github.com/broadinstitute/picard)
and Bedtools (v2.17.0) were used to assess coverage.
Variant calling was performed using Samtools and anno-
tated using the Annovar tool [15]. We optimised the
calling based on a set of variants that were positive con-
trols, and Samtools was the optimal caller compared to
HaplotypeCaller from GATK. The transcript that was
used for each gene is reported in Additional file 1. The
frequency of variant alleles from European reference
populations was obtained from three sources (1000 ge-
nomes, ESP, ExAC), Additional file 2.
Variants were further filtered based on read depth,
quality score, and genotypic quality. All variants with a
read depth < 10, quality score < 20, or genotypic score <
20 were excluded from the analysis. In addition, variants
with an allelic ratio < 0.2 were excluded irrespective of
read depth and variants with an allelic ratio < 0.3 and
read depth < 50 were also removed.
Variants that had been previously clinically evaluated
and deposited in the ClinVar database (https://www.
ncbi.nlm.nih.gov/clinvar/) were assigned labels of be-
nign, variants of unknown significance (VUS), conflict-
ing or pathogenic, as per ClinVar.
Variants not present in the ClinVar database were con-
sidered pathogenic if they were predicted to lead to pro-
tein truncation (frameshift indels, stop-gain, stop-loss or
intronic variants within two base pairs of the splicing
junction; Additional file 3) and variants of unknown sig-
nificance (VUS) if they were nonsynonymous substitu-
tions or in-frame indels. Novel variants in the last exon
of a gene meeting the above criteria of pathogenic were
not excluded as, although unlikely to result in loss of
function through nonsense mediated decay, these vari-
ants may have substantial impact on the protein prod-
uct. However, no such variants were detected in this
study.
To further investigate the importance and validity of
our findings, we used an external resource of controls. A
non-Finnish European population of controls from gno-
mAD (gnomAD controls v2.1) was used as a replication
control cohort.
Statistical analysis
Fisher’s exact test was used for gene based rare variant
analysis for both case-control and case-only analyses.
One sided test was selected since the expectation was
enrichment rather than deficit of variants in cases over
controls. No adjustments have been made to account for
multiple testing. With the current sample size, we have
~ 80% power (alpha =0.05) to detect variants of com-
bined allele frequency = 0.001 and an effect size of OR
= 5.
Validation
All putative pathogenic alleles identified by the above
methods were confirmed by Sanger sequencing.
Assessment of copy number variation
Two bioinformatics tools were used to assess copy num-
ber variation (CNV) in our sequencing data: CNVkit
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version 0.9.5 [16] and ONCOCNV version 6.9 [17]. The
first, CNVkit, running in amplicon sequencing mode,
was used to identify exon-level copy number variations
using on-target coverages alone. One thousand six hun-
dred eleven control samples were used to construct a
reference copy number profile, and the default circular
binary segmentation (CBS) algorithm was used to derive
segments. The second, ONCOCNV, is a package specific-
ally designed for amplicon sequencing data. Fifteen ran-
domly selected control samples were used to construct the
reference copy number profile, and the default cghseg algo-
rithm was used to derive segments. All CNVs detected by
these methods underwent multiplex ligation-dependent
probe amplification (MLPA) using MRC Holland kits
(https://www.mlpa.com/) in order to validate the finding.
DNA samples were amplified, and PCR products were ana-
lysed on the ABI 3730 Genetic Analyser (Applied Biosys-
tems) using TAMRA 500, as per the manufacturer’s
instructions. Coffalyser (MRC Holland) was used to call ex-
onic deletions/rearrangements.
Results
The analysis was performed on 655 cases of pure DCIS
with no invasive disease diagnosed in women aged under
50, together with 1611 controls. The median age of cases
was 45 years (interquartile range 6) and of controls was
52 (interquartile range 12). Data on grade and oestrogen
receptor (ER) status were available for 98% and 73% of
the cases in the study, respectively, Table 1.
The mean coverage of our target region was 800 reads
across all samples, with an average of at least 40 reads for
more than 98% of the target region per sample. Of the 321
amplicons analysed, seven failed to amplify consistently
across the majority of the samples; however, even for these
seven the majority of samples had at least 10 reads for 90%
of the amplicon, and there was no difference in amplifica-
tion between cases and controls, Additional file 4. No
exon-level CNVs were identified using CNVkit version
0.9.5. Thirteen copy number variants across eight samples
were detected by ONCOCNV; however, none were con-
firmed using MLPA, Additional file 5.
We found an association with DCIS and pathogenic
variants in BRCA2, CHEK2, PALB2, BRCA1 and TP53,
Table 2 (individual raw data, Additional file 2).
BRCA2
The strongest association was with BRCA2 (OR= 27.96,
95%CI 6.56–119.26, P= 2 × 10−10), Table 2, Fig. 1a. Of the 22
pathogenic variants identified, all had been previously de-
scribed apart from a novel frameshift in exon 11
(c.5754dupT:p.H1918fs). Fifty percent of pathogenic variants
occurred in exon 11. Only two pathogenic variants occurred
in more than one patient: exon20:c.8575delC:p.Q2859fs in
two patients and exon25:c.C9382T:p.R3128X in two patients,
Additional file 6. Ninety-five percent of the cases with a
pathogenic variant in BRCA2 had high or intermediate grade
DCIS, and in the 15 cases where ER status was known, all
were ER positive. There was also an association with age <
40 years (OR= 4.12, 95%CI 1.75–9.69, P= 0.003), Table 3,
and family history of breast cancer in a first-degree relative
(OR= 4.29, 95%CI 1.82–10.08, P= 0.001), Table 4.
CHEK2
CHEK2 also showed a strong association with DCIS
(OR = 8.04, 95%CI 2.93–22.05, P = 9 × 10− 6), but with a
smaller effect size than BRCA2, Table 2, Fig. 1b. Of the
16 pathogenic variants detected, 13 were the c.1100delC
mutation. The remaining three variants were novel
frameshift mutations, one in exon 3: c.401_402del, and
two in exon 12: c.1262delT and c.1368dupA, Add-
itional file 7. Again, all were high or intermediate grade
DCIS and, of the 14 with known ER status, 12 were ER
positive. There was no association with age < 40 (81% of
cases occurred in the 40–49 age group) or family history,
Tables 3 and 4.
PALB2
There was an association with PALB2 (OR 14.88, 95%CI
1.79–123.88, P = 0.003), Table 2, but this was weaker
than that for BRCA2 and CHEK2. Of the six pathogenic
PALB2 variants detected, three were novel frameshifts
Table 2 Association of known pathogenic variants and DCIS in women < 50 years of age by gene. For the GnomAD comparison,
Non-Finnish European controls were used (v2.1)
Gene Pathogenic variants
in cases (N = 655)
Pathogenic variants in
controls (N = 1611)
OR (95% CI) P value Pathogenic variants
in gnomAD controls
(N = 21,384)
OR (95% CI)
(vs gnomAD controls)
P value
(vs gnomAD controls)
BRCA2 22 (3.4%) 2 (0.1%) 27.96 (6.56–
119.26)
2 ×
10−10
76 (0.35%) 9.74 (6.02–15.76) 1 × 10−13
CHEK2 16 (2.4%) 5 (0.3%) 8.04 (2.93–22.05) 9 × 10−6 144 (0.67%) 3.69 (2.19–6.23) 2 × 10−5
PALB2 6 (0.9%) 1 (0.06%) 14.88 (1.79–
123.88)
0.003 22 (0.1%) 8.98 (3.63–22.21) 1 × 10−4
BRCA1 4 (0.6%) 0 (0%) inf 0.007 81 (0.38%) 1.62 (0.59–4.42) 0.32
TP53 3 (0.5%) 0 (0%) inf 0.02 16 (0.07%) 6.14 (1.79–21.14) 0.018
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(two in exon 4, one in exon 5, Fig. 1c, Additional file 8).
Of the three known, two were in exon 10 (rs180177132),
which has previously been shown to be associated with
breast cancer (OR = 4.21, 95%CI 1.85–9.61), but with no
evidence of a differential association with ER status [18].
All women with PALB2 pathogenic variants had high or
intermediate grade DCIS and were ER positive. There
was no association with age < 40, but there was an
association with family history of breast cancer in a
first-degree relative (OR = 14.37, 95%CI 1.68–123.25, P
= 0.006), Table 4.
BRCA1
There were four DCIS cases that were found to harbour
pathogenic BRCA1 germline variants and no controls
((P = 0.007), Table 2, Additional file 9. One was the
Fig. 1 Position of pathogenic variants in DCIS cases in a BRCA2, b CHEK2, c PALB2, d BRCA1
Table 3 Case only analysis of pathogenic variants in DCIS by age
Gene Pathogenic variants in cases aged < 40 (N = 100) Pathogenic variants in cases aged 40–49 (N = 555) OR (95% CI) P value
BRCA2 9 (9%) 13 (2.3%) 4.12 (1.75–9.69) 0.003
CHEK2 3 (3%) 13 (2.3%) 1.29 (0.37–4.54) 0.72
PALB2 1 (1%) 5 (0.9%) 1.11 (0.13–9.53) 1
BRCA1 1 (1%) 3 (0.5%) 1.86 (0.19–17.90) 0.485
TP53 1 (1%) 2 (0.4%) 2.79 (0.25–30.86) 0.39
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well-described exon12:c.C4327T:p.R1443X, and the
other three were novel frameshift mutations, two in
exon 11 and one in exon 3. Three were ER negative (one
unknown) and three high-grade DCIS. There was no as-
sociation with age < 40 and a borderline association with
family history of breast cancer in a first-degree relative
(P = 0.058). Three of the cases had a family history of
breast and or ovarian cancer in first-degree relatives
under the age of 50. However, the case with the novel
frameshift variant in exon 10: c.3750delG:p.E1250fs had
a strong family history of other cancers (cervical, lung,
and oral) but not breast.
TP53
There were three DCIS cases that were found to harbour
pathogenic TP53 germline variants and no controls ((P
= 0.02), Table 2. Two were stopgain variants (one novel),
and the other a nonsynomous variant (rs397514495)
considered pathogenic in the literature [19], but recently
suggested to be a VUS as it does not disrupt all the func-
tions of TP53 just apoptosis [20], Additional file 10a.
The women that carried these variants did not meet the
criteria for classic Li-Fraumeni or Li-Fraumeni-like syn-
drome. The novel stopgain variant (NM_000546:ex-
on4:c.G272A:p.W91X) was found in a woman with
bilateral DCIS at age 35 and a first-degree relative with
breast cancer < 40 years, but no other cancers. The other
known stopgain variant was identified in a woman with
DCIS at age 40 whose father developed an unknown
cancer at age 50 but with no other family history of can-
cer. The missense variant occurred in a woman with
DCIS at age 45 and a family history of breast cancer in a
second-degree relative aged 60, but no other cancers.
Again, all had intermediate or high-grade DCIS, with
two ER positive and two ER negative (in the bilateral
case one side was ER positive and the other ER
negative).
As most pathogenic germline mutations in TP53 are
missense rather than truncating mutations [21], it is pos-
sible that by only considering novel variants as patho-
genic if they were predicted to lead to protein truncation
we may have missed novel pathogenic missense variants
in TP53. We therefore looked at these in more detail.
Only one novel missense variant was detected,
NM_000546:exon10:c.G1054 T:p.D352Y, and this was in
a control. Three variants called as VUS in the ClinVar
database were identified in cases, Additional file 10b.
One NM_000546:exon8:c.G869A:p.R290H is listed in
the IARC TP53 database [22] as being associated with
Li-Fraumeni–like syndrome and, in our study, was found
in one case and two controls.
Biallelic mutation carriers
There were four patients carrying two pathogenic variants
in different genes. All had a family history of cancer and
three a family history of breast cancer, Additional file 11.
Bilateral and subsequent invasive disease
Metachronous bilateral disease was most commonly
found in CHEK2 mutation carriers with 5/16 (31%) de-
veloping subsequent contralateral disease after a diagno-
sis of unilateral DCIS (in two, this was in the form of an
invasive disease, in two LCIS and in one DCIS) com-
pared to 2/22 (9%) for BRCA2. The latter, however, will
be influenced by the fact that nine of the BRCA2 carriers
elected for bilateral prophylactic mastectomies based on
their family history or the results of genetic testing (five
underwent genetic testing). As this study does not have
long-term follow-up data, it was not possible to assess
whether germline pathogenic variants were associated
with subsequent invasive recurrence of DCIS.
Variants of unknown significance
Analysis of variants of unknown significance (VUS), either
known or novel, revealed no excess of VUS in BRCA2,
PALB2, TP53 or BRCA1, Additional file 12. A VUS in
exon 4 of CHEK2 (rs77130927, c.C538T:p.R180C), which
we have previously shown to have a borderline association
with invasive lobular cancer (ILC) (P = 0.03, Petridis et al,
accepted Cancer Epidemiology, Biomarkers & Prevention),
was found in two DCIS cases and one control.
Discussion
Early data on women with BRCA1 and BRCA2 muta-
tions suggested that presentation as pure DCIS was in-
frequent. However, Yang et al. showed that ~ 60% of
Table 4 Case only analysis of pathogenic variants in DCIS for family history of breast cancer
Gene Carriers with FH of BC in first degree relative vs no FH Carriers with FH of BC in any relative vs no FH
OR (95% CI) P OR (95% CI) P
BRCA2 4.29 (1.82–10.08) 0.001 4.90 (1.65–14.54) 0.002
CHEK2 0.93 (0.30–2.90) 1 1.76 (0.64–4.86) 0.32
PALB2 14.37 (1.68–123.25) 0.006 5.27 (0.61–45.20) 0.12
BRCA1 8.52 (0.88–82.07) 0.058 3.14 (0.33–30.26) 0.36
TP53 1.40 (0.13–15.47) 1 2.09 (0.19–23.07) 0.62
FH family history, BC breast cancer
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BRCA1- and BRCA2-associated invasive tumours had
associated DCIS of similar phenotype [23]. They also
found that the number of pure DCIS cases was similar
in BRCA1 and BRCA2 mutations carriers (21% vs 23%),
in contrast to Krammer et al. who reported that pure
DCIS was more frequent in BRCA2 mutation carriers
compared to BRCA1 carriers (5%, 36/246, versus 9%, 23/
250, P = 0.0026) [24]. In our study of sporadic pure
DCIS, pathogenic BRCA2 variants were far more com-
mon than BRCA1 mutations (3.5% vs 0.6%). This is simi-
lar to the data of Claus et al. [12] who found that 2.4%
had pathogenic variants in BRCA2 and 0.8% in BRCA1
in a slightly older group of DCIS patients (mean age
53.8 years). Similarly, Hall et al. found that 5.2% of
women under 50 years of age with carcinoma in situ
(LCIS and DCIS) had BRCA1/2 mutations, with BRCA2
mutations being more common than BRCA1 [13].
We found that BRCA2 mutations occurred in 2.4% of
DCIS in women under the age 50 and in 9% under the
age of 40. All but one of these variants had been previ-
ously described in invasive breast cancer. Of the genes
studied, BRCA2 was the only gene where pathogenic
mutations were associated with younger age. All the
cases of DCIS in BRCA2 carriers were ER positive
(where ER status was known), unlike invasive disease
where only 77% are ER positive [25]. In contrast, BRCA1
pathogenic variants were infrequent, four in total (only
one had been previously described), and associated with
predominantly ER negative DCIS.
Pathogenic variants in CHEK2 were the second most
common set of mutations after BRCA2 and occurred in
2.5% of pure DCIS under the age of 50. Unlike BRCA2,
there was no association with age and the majority were
the well-described c.1100delC variant. There was no evi-
dence of an association with the rare missense variant
p.I157T (c.T470C, rs17879961), which was found in
three controls and no cases. This high frequency of
CHEK2 variants in pure DCIS has not been previously
described, although Schmidt et al. noted in their study
of tumour characteristics in CHEK2 c.1100delC carriers
that carriers from population- and hospital-based studies
more often developed in situ tumours (LCIS and DCIS)
compared to carriers from familial or clinical genetics
center–based studies; this was interpreted as a bias esti-
mate due to differential recruitment related to family
history of breast cancer and screening [26]. Our findings
are also supported by Couch et al. who reported data on
the frequency of CHEK2 mutations in a series of breast
cancer with and without pure DCIS allowing one to de-
termine mutation rates in pure DCIS cases. In that
study, 2.87% of DCIS cases had pathogenic CHEK2 vari-
ants compared to 1.43% in invasive disease [27].
The tumour phenotypes associated with PALB2 tu-
mours are very similar to those associated with BRCA2
tumours, with 61% of invasive tumours having associ-
ated DCIS [28]. It is therefore not surprising that we
have found PALB2 pathogenic mutations in women with
pure DCIS and that they are more common in women
with a first-degree relative with breast cancer. However,
unlike BRCA2, they were not associated with age < 40
years, this is supported by the findings of Antoniou et al.
who showed there was a constant relative risk, irrespect-
ive of age, for pathogenic variants in PALB2 [29]. The
frequency of PALB2 variants in our data is supported by
the study by Couch et al. where one can infer from the
supplementary data that the frequency of pathogenic
PALB2 variants in DCIS is 0.96% [27].
Pure DCIS (73% HER2 positive, 55% ER positive) and
high-grade comedo DCIS have been described in
Li-Fraumeni Syndrome [30, 31] but our data show that
TP53 mutations are infrequent in sporadic DCIS. Al-
though two of three pathogenic variants identified had
been previously described, none of the women had a
family history of cancer to suggest Li-Fraumeni Syn-
drome (LFS).This may be because they are de novo mu-
tations or because two were loss of function mutations
which often do not have such a typical LFS phenotype as
dominant negative missense mutations [32]. The known
missense mutation detected has been shown to be asso-
ciated with Li-Fraumeni–like syndrome rather than true
LFS [22].
The odds ratios presented in this study are higher than
those previously reported for these genes in invasive dis-
ease. This is likely due to the size of the study which is
too small to yield stable estimates of associations with
DCIS, but does give useful estimates of prevalence and,
of note, is twice as large as the study by Claus et al., the
only other study documenting the prevalence of BRCA1/
2 mutations in sporadic DCIS. The other reason is due
to the use of older controls. When we compare our
cases to 21,384 non-Finnish European controls from
gnomAD (gnomAD controls v2.1, http://gnomad.broad-
institute.org), we see that the odds ratios fall to similar
levels previously reported for invasive cancer with the
exception of CHEK2 (OR = 3.69, 95%CI.19–6.23) which
still remains higher than that reported in studies of inva-
sive breast cancer (OR~ 2), Table 2. Schmidt et al. also
found this in their large series from the Breast Cancer
Association Consortium (invasive: OR = 2.4, 95%CI
2.04–2.82, in situ: OR = 3.53, 95%CI 2.38–5.23) [26]).
We also found a similar finding in lobular cancer where
LCIS had a stronger association with CHEK2 mutations
than ILC (ILC OR = 4.29, 95%CI 1.60–11.51, P = 0.0017;
LCIS OR = 9.95, 95%CI 3.44–28.82, P = 5 × 10−5, Petridis
et al. accepted Cancer Epidemiology, Biomarkers & Pre-
vention). This suggests that CHEK2 pathogenic variants
may be predisposing to the in situ stage of breast cancer
with some not progressing to the invasive state.
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In a study of 6478 patients with invasive breast cancer
under the age of 50, Schmidt et al. [33] found a higher
frequency of BRCA1 mutations compared to our study
of DCIS (3.2% versus 0.6%). We believe that this differ-
ence in frequency of BRCA1 mutations stems from the
fact that the vast majority of the samples in our study
are ER+ and only 13% of the samples are ER−, compared
to 25% in the invasive study of Schmidt et al.
There is currently a debate as to the need for mutation
screening in women with DCIS. In this study, 7.2% of
women with DCIS (irrespective of ER status) under the
age of 50 had pathogenic variants in one of five known
breast cancer predisposition genes. This level does not
reach the current UK threshold for genetic testing
(https://www.nice.org.uk/guidance/cg164/chapter/
Recommendations#genetic-testing); however, women
under 40 years of age had a 13% (11% excluding CHEK2
variants) probability of having a germline mutation
which does reach the UK threshold of 10% for routine
testing. For women under 40 years of age with a family
history of breast cancer, the frequency of germline muta-
tions increases to 21%.
There has been particular focus on ER-negative DCIS
and whether these women should undergo HER2 testing
and, if this is also negative, be offered BRCA1 and
BRCA2 testing, as is recommended for those with
triple-negative invasive breast cancer. Unfortunately, in
our series, we did not have data on HER2 receptor status
as it is not routinely assessed in cases of DCIS in present
clinical practice. However, looking solely at ER-negative
DCIS, only 9% under the age of 50 and 8% under the
age of 40 had pathogenic variants and these were in
BRCA1, TP53 and CHEK2. These figures rise to 16%
and 11%, respectively, if only women with a family his-
tory of breast cancer are considered, Table 5. In contrast,
the frequency of pathogenic variants in ER-positive
DCIS under the age of 40 was much higher; 9% of
women under the age of 50 had pathogenic variants ris-
ing to 29% under the age of 40 (14% and 42%, respect-
ively, if only women with a family history of breast
cancer are considered) Table 6.
Conclusions
This study has shown that a DCIS-associated malignant
pathway can occur in patients who have pathogenic vari-
ants in BRCA2, CHEK2, PALB2, BRCA1 and TP53. We
also show that the focus of genetic testing should be on
ER-positive, intermediate-, and high-grade DCIS from
patients under the age of 40, rather than ER-negative
DCIS, although restricting such testing to those age
under 40 would fail to identify the majority of CHEK2
and PALB2 mutation carriers. Once mutations are iden-
tified in these women, chemoprevention with tamoxifen
and surveillance is a potential alternative to prophylactic
mastectomy, particularly in CHEK2 carriers where the
risk of invasive disease is less. Further studies with
Table 5 Frequency of pathogenic variants in ER-negative DCIS by age
Gene Frequency under 40 years
N = 26
Frequency under 40 years with FH
N = 9
Frequency under 50 years
N = 89
Frequency under 50 years with FH
N = 38
BRCA2 0 (0%) 0 (0%) 0 (0%) 0 (0%)
CHEK2 1 (3.8%) 0 (0%) 3 (3.3%) 2 (5.2%)
PALB2 0 (0%) 0 (0%) 0 (0%) 0 (0%)
BRCA1 0 (0%) 0 (0%) 3 (3.3%) 3 (7.9%)
TP53 1 (3.8%) 1 (11%) 2 (2.2%) 1 (2.6%)
Total (% of ER− cases) 2 (8%) 1 (11%) 8 (9%) 6 (16%)
FH family history of breast cancer in any relative
Table 6 Frequency of pathogenic variants in ER-positive DCIS by age
Gene Frequency under 40 years
N = 45
Frequency under 40 years with
FH N = 24
Frequency under 50 years N
= 397
Frequency under 50 years
with FH
N = 197
BRCA2 8 (17.8%) 7 (29.2%) 16 (4%) 14 (7.1%)
CHEK2 2 (4.4%) 1 (4.2%) 12 (3%) 7 (3.6%)
PALB2 1 (2.2%) 1 (4.2%) 5 (1.3%) 4 (2%)
BRCA1 1 (2.2%) 0 (0%) 1 (0.3%) 0 (0%)
TP53 1 (2.2%) 1 (4.2%) 2 (0.5%) 2 (1%)
Total (% of ER+
cases)
13 variants (29%) in 11 women
(24%)*
10 variants (42%) in 9 women
(38%)
36 variants (9%) in 32
women (8%)
27 variants (14%) in 24
women (12%)
FH family history of breast cancer in any relative
*Some individuals carry 2 variants
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long-term follow-up data are required to ascertain
whether these germline pathogenic variants identify a
subgroup of DCIS that are more likely to progress to in-
vasive disease or whether somatic changes in the DCIS
are a more important predictor of recurrence.
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